Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Nov 14, 2024 4:26pm
64 Views
Post# 36313588

RE:RE:RE:Looming Big Pharma Patent Cliff

RE:RE:RE:Looming Big Pharma Patent CliffQuentin30 posted another of his falsehoods when he says :  "... back then of course you were valuing ONCY at over 10 Billion..." Really?? Show me where I  said that. Post the link.  In fact what I posted was the law firm of Morgan Lewis of Boston MA, sees a continuation of M&A "sweetspot" of between US$5 Billion and US$15 Billion for 2024. Why do you fabricate so many things? 

Comment by Noteableon May 05, 2024 10:52am
72 Views 
Post# 36023832

RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

According to the law firm of Morgan Lewis of Boston, MA.,  " In 2024, we expect M&A will more closely resemble prior years with a total deal value in the $225 billion to $275 billion range across all subsectors of the life sciences industry. We continue to expect that deals in the $5 billion to $15 billion range will be the market sweet spot but see the potential for one or more deals in the $20 billion to $40 billion range before year-end."

<< Previous
Bullboard Posts
Next >>